AI Summary
We reviewed 13 live results for truxima (rituximab) and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Oncology and Biosimilar.
Comparison Table
Recommended
Truxima
Source: Celltrion Healthcare Singapore Private Limited
Description
Truxima is a rituximab biosimilar used in Singapore for oncology and autoimmune indications, including non-Hodgkin's lymphoma and rheumatoid arthritis. It targets B-cells to treat hematological malignancies and chronic inflammation.
Best for
non-Hodgkin's lymphoma, B-cell targeted therapy and leukemia treatment
View Details
Rating
Truxima (Rituximab)
Source: Celltrion Healthcare Philippines Inc.
Description
Truxima is the first oncology monoclonal antibody biosimilar in the Philippines, listed in the Philippine National Formulary for cancer treatment.
Best for
oncology patients, monoclonal antibody therapy and formulary-listed treatments
View Details
Rating
Truxima (rituximab-abbs)
Source: Teva Pharmaceuticals
Description
Truxima (rituximab-abbs) is a CD20-directed cytolytic antibody and was the first FDA-approved biosimilar to Rituxan. It is indicated for adult patients with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA) in combination with methotrexate, Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Pemphigus Vulgaris (PV). The medication is administered as an intravenous (IV) infusion by healthcare professionals and is available in 100 mg/10 mL and 500 mg/50 mL single-dose vials. Teva provides a cost support program for eligible commercially insured patients.
Best for
Adults with Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia treatment, Moderate-to-severe Rheumatoid Arthritis, Patients seeking Rituxan biosimilars and Intravenous infusion therapy
View Details
Rating
| Compare | Truxima | Truxima (Rituximab) | Truxima (rituximab-abbs) |
|---|---|---|---|
| Source | Celltrion Healthcare Singapore Private Limited | Celltrion Healthcare Philippines Inc. | Teva Pharmaceuticals |
| Description | Truxima is a rituximab biosimilar used in Singapore for oncology and autoimmune indications, including non-Hodgkin's lymphoma and rheumatoid arthritis. It targets B-cells to treat hematological malignancies and chronic inflammation. | Truxima is the first oncology monoclonal antibody biosimilar in the Philippines, listed in the Philippine National Formulary for cancer treatment. | Truxima (rituximab-abbs) is a CD20-directed cytolytic antibody and was the first FDA-approved biosimilar to Rituxan. It is indicated for adult patients with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA) in combination with methotrexate, Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Pemphigus Vulgaris (PV). The medication is administered as an intravenous (IV) infusion by healthcare professionals and is available in 100 mg/10 mL and 500 mg/50 mL single-dose vials. Teva provides a cost support program for eligible commercially insured patients. |
| Best for | non-Hodgkin's lymphoma, B-cell targeted therapy and leukemia treatment | oncology patients, monoclonal antibody therapy and formulary-listed treatments | Adults with Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia treatment, Moderate-to-severe Rheumatoid Arthritis, Patients seeking Rituxan biosimilars and Intravenous infusion therapy |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Truxima from Celltrion Healthcare Singapore Private Limited."
I picked this because Truxima is a well-established rituximab biosimilar in Singapore that increases patient access to vital lymphoma and leukemia treatments.
Share this search
Related Finds